Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Seres Therapeutics (1S90) Stock Price & Analysis

1 Followers

1S90 Stock Chart & Stats

€1.49-€0.15(-9.38%)
At close: 5:30 PM GMT+1
€2€2.5€3Oct 7Oct 23Nov 5
Day’s Range
EUR 1.48 - EUR 1.49
52-Week Range
EUR 1.48 - EUR 24.45
Previous Close
EUR 1.64
Volume
N/A
Average Volume (3M)
32
Market Cap
EUR 14.24M
Enterprise Value
EUR 51.68M
Total Cash (Recent Filing)
EUR 17.53M
Total Debt (Recent Filing)
EUR 35.77M
Price to Earnings (P/E)
―
Beta
-2.28
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
-0.58
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Revenue is still modest, but year-over-year growth indicates early commercial or partnership traction in the company’s microbiome therapeutics platform. If sustained, expanding revenue can improve operating leverage and provide a broader base for funding development over the next several quarters.

Improved Balance Sheet

Debt reduction and a return to positive equity represent a meaningful improvement from the company’s most stressed periods. A stronger capital structure can reduce immediate balance-sheet pressure and preserve more flexibility to advance programs, despite continued losses and elevated leverage.

SER-155 Clinical Potential

The reported investigator-sponsored results provide early clinical support for SER-155 in immune checkpoint inhibitor-related enterocolitis. A preventive therapy that helps patients remain on cancer immunotherapy could expand the addressable opportunity and strengthen the platform’s strategic relevance.

Bears Say

Deep Operating Losses

Operating losses remain dramatically larger than the current revenue base, showing that the business has not yet achieved viable operating leverage. Persistent losses can require additional financing, constrain investment choices, and make future earnings dependent on successful commercial scaling.

Persistent Cash Burn

Substantial ongoing cash consumption means operations are not funding themselves and development depends on external capital or other financing sources. This weakens financial resilience, raises the importance of successful program execution, and can limit the pace of sustainable expansion.

Elevated Leverage

Although debt has declined, leverage remains high relative to the company’s scale and is paired with deeply negative returns. This combination leaves less room to absorb setbacks, increases financial obligations while profitability is absent, and complicates funding of later-stage programs.

Seres Therapeutics News

1S90 FAQ

What was Seres Therapeutics’s price range in the past 12 months?
Seres Therapeutics lowest stock price was €1.48 and its highest was €24.45 in the past 12 months.
What is Seres Therapeutics’s market cap?
Seres Therapeutics’s market cap is €14.24M.
When is Seres Therapeutics’s upcoming earnings report date?
Seres Therapeutics’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 111 days.
How were Seres Therapeutics’s earnings last quarter?
Seres Therapeutics released its earnings results on Nov 04, 2026. The company reported -€1.459 earnings per share for the quarter, missing the consensus estimate of -€0.9 by -€0.56.
Is Seres Therapeutics overvalued?
According to Wall Street analysts Seres Therapeutics’s price is currently Undervalued.
Does Seres Therapeutics pay dividends?
Seres Therapeutics does not currently pay dividends.
What is Seres Therapeutics’s EPS estimate?
Seres Therapeutics’s EPS estimate is -0.58.
How many shares outstanding does Seres Therapeutics have?
Seres Therapeutics has 10,195,031 shares outstanding.
What happened to Seres Therapeutics’s price movement after its last earnings report?
Seres Therapeutics reported an EPS of -€1.459 in its last earnings report, missing expectations of -€0.9. Following the earnings report the stock price went down -4.108%.
Which hedge fund is a major shareholder of Seres Therapeutics?
Hedge funds hold Seres Therapeutics shares: the largest hedge-fund position in Seres Therapeutics is 1,473,521,736 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology